Inhalable curcumin: Offering the potential for translation to imaging and treatment of Alzheimer's disease

Richard McClure, Daijiro Yanagisawa, Donald Stec, Dave Abdollahian, Dmitry Koktysh, Dritan Xhillari, Rudolph Jaeger, Gregg Stanwood, Eduard Chekmenev, Ikuo Tooyama, John C. Gore, Wellington Pham

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

Curcumin is a promising compound that can be used as a theranostic agent to aid research in Alzheimer's disease. Beyond its ability to bind to amyloid plaques, the compound can also cross the blood-brain barrier. Presently, curcumin can be applied only to animal models, as the formulation needed for iv injection renders it unfit for human use. Here, we describe a novel technique to aerosolize a curcumin derivative, FMeC1, and facilitate its safe delivery to the brain. Aside from the translational applicability of this approach, a study in the 5XFAD mouse model suggested that inhalation exposure to an aerosolized FMeC1 modestly improved the distribution of the compound in the brain. Additionally, immunohistochemistry data confirms that following aerosol delivery, FMeC1 binds amyloid plaques expressed in the hippocampal areas and cortex.

Original languageEnglish (US)
Pages (from-to)283-295
Number of pages13
JournalJournal of Alzheimer's Disease
Volume44
Issue number1
DOIs
StatePublished - 2015

Keywords

  • Aerosol
  • Alzheimer's disease
  • Amyloid imaging
  • Amyloid plaques
  • Atomization
  • Clinical translation
  • Curcumin
  • Inhalation exposure

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Inhalable curcumin: Offering the potential for translation to imaging and treatment of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this